Application of sanguisorba sapogenin in preparation of medicine for treating gout

Abstract

The invention discloses an application of sanguisorba officinalis sapogenin in preparation of a medicine for treating gout. Compared with the prior art, it is found for the first time that sanguisorba sapogenin can treat gout, especially acute gouty arthritis. Animal research proves that the sanguisorba sapogenin can remarkably relieve joint swelling and tissue damage caused by acute gouty arthritis by inhibiting release of inflammatory factors such as IL-1beta and TNF-alpha. Meanwhile, the sanguisorba sapogenin can also remarkably reduce the level of serum uric acid, and also has a certain treatment effect on gout in a remission stage and a chronic stage. Therefore, the sanguisorba officinalis sapogenin can be used for treating gout and has the potential and prospect of being prepared into the anti-gout medicine.

Description

Technical Field

[0001] This invention belongs to the field of new pharmaceutical applications, and specifically relates to the application of sanguisorbin in the preparation of drugs for treating gout. Background Technology

[0002] Gout is a metabolic disease caused by purine metabolism disorders or uric acid excretion disorders. Based on hyperuricemia, it leads to the deposition of urate crystals in joints, soft tissues, and kidneys, causing inflammation and tissue damage. Common causes include: Purine metabolism disorders: Excessive breakdown of purines in the body leads to increased uric acid production (e.g., genetic defects or a high-purine diet). Decreased uric acid excretion: Approximately 90% of patients experience uric acid retention due to abnormal renal uric acid excretion function. Dietary factors: Long-term consumption of high-purine foods (animal organs, seafood), alcohol (especially beer), and sugary drinks. Obesity and metabolic syndrome: Obesity, hypertension, and hyperglycemia are closely related to the onset of gout. Lifestyle factors: Sedentary lifestyle, staying up late, and high stress can affect uric acid metabolism. Acute gouty arthritis is the typical symptom of gout, mainly characterized by sudden, severe pain, swelling, and increased skin temperature in a single joint (such as the first metatarsophalangeal joint or ankle joint), with limited mobility, often occurring at night or in the early morning.

[0003] In the acute phase of gout, anti-inflammatory and analgesic treatments are typically used, such as nonsteroidal anti-inflammatory drugs (NSAIDs) (e.g., indomethacin) or colchicine, to quickly relieve inflammation and pain, or glucocorticoids. Treatment during remission and the chronic phase usually involves uric acid-lowering drugs to inhibit uric acid production, such as febuxostat and allopurinol. However, these drugs have significant side effects and are prone to drug resistance, necessitating the search for effective alternatives. Summary of the Invention

[0004] Purpose of the invention: In order to overcome the shortcomings of the prior art, the present invention provides the application of sanguisorbin in the preparation of drugs for treating gout.

[0005] Technical solution: To achieve the above-mentioned objectives, the present invention adopts the following technical solution:

[0006] In a first aspect, the present invention provides the application of sanguisorbin in the preparation of drugs for treating gout.

[0007] As a preferred embodiment, the use of the sanguisorbin in the preparation of a drug for treating acute gouty arthritis.

[0008] As a specific implementation plan, the application of sanguisorbin as the sole active ingredient in the preparation of drugs for treating gout.

[0009] As a specific implementation plan, the gout treatment drug is an oral medication.

[0010] As a further option, the oral medication may be in the form of tablets, capsules, powders, granules, or oral liquids.

[0011] Secondly, the present invention provides the use of a pharmaceutical composition containing sanguisorbin in the preparation of a drug for treating gout.

[0012] As a preferred embodiment, the pharmaceutical composition comprising sanguisorbin is used in the preparation of a medicament for treating acute gouty arthritis.

[0013] In a specific implementation scheme, sanguisorbin is the sole active ingredient in the pharmaceutical composition.

[0014] As a specific implementation, the pharmaceutical composition includes sanguisorbinogen and pharmaceutically acceptable excipients or carriers.

[0015] As a specific implementation, the dosage form of the pharmaceutical composition is selected from tablets, capsules, powders, granules, or oral liquids.

[0016] The sanguisorbinogen described in this invention has CAS Registry Number: 6812-98-2 and molecular formula: C 30 H 46 O3, with a molecular weight of 454.7, has the following chemical structural formula:

[0017]

[0018] Beneficial Effects: Compared with existing technologies, this invention is the first to discover that sanguisorbin can treat gout, especially acute gouty arthritis. Animal studies of this invention have confirmed that sanguisorbin can significantly alleviate joint swelling and tissue damage in acute gouty arthritis by inhibiting the release of inflammatory factors such as IL-1β and TNF-α. Simultaneously, sanguisorbin can also significantly reduce serum uric acid levels, showing a certain therapeutic effect on gout in both remission and chronic phases. Therefore, sanguisorbin has the potential and prospect of being used to treat gout and is suitable for the development of anti-gout drugs. Detailed Implementation

[0019] The technical solutions in the embodiments of the present invention will be clearly and completely described below. Where specific conditions are not specified in the embodiments, conventional conditions or conditions recommended by the manufacturer shall apply. Reagents or instruments whose manufacturers are not specified are all conventional products that can be purchased commercially.

[0020] Example 1

[0021] I. Experimental Materials

[0022] 1. Laboratory animals

[0023] SPF-grade male Balb / c mice, 8 weeks old and weighing 20±2g, were randomly divided into 6 groups (normal control group, model group, positive control group, and low / medium / high dose groups of sanguisorbin), with 10 mice in each group.

[0024] 2. Reagents and Drugs

[0025] Modeling agent: Sodium urate (MSU) crystal suspension (25 mg / mL, prepared with sterile physiological saline);

[0026] Treatment drug: Sanguisorbin (purity ≥98%, soluble in physiological saline, low dose 10mg / kg, medium dose 20mg / kg, high dose 30mg / kg);

[0027] Positive control: colchicine (0.3 mg / kg);

[0028] Test reagents: ELISA kit (IL-1β, TNF-α), serum uric acid test kit.

[0029] 3. Instruments and equipment

[0030] Vernier calipers (for measuring joint swelling), ELISA reader, pathology slide machine, microscope.

[0031] II. Experimental Methods

[0032] 1. Model Establishment

[0033] Establishment of an acute gouty arthritis model: After 7 days of acclimatization, mice in the model group and each treatment group were injected intra-articularly with 50 μL MSU suspension in the right hind limb; the normal control group was injected with an equal volume of physiological saline. The grouping and administration regimens are shown in the table below:

[0034]

[0035] 2. Indicator Measurement

[0036] Joint swelling: Ankle joint diameter was measured at 6, 12, 24 and 48 hours after modeling, and swelling rate was calculated (swelling rate = diameter of modeling side / diameter of control side × 100%).

[0037] Serum inflammatory factors: Blood was collected 24 hours after the last administration, and the levels of IL-1β and TNF-α were detected by ELISA.

[0038] Serum uric acid: This measures the level of serum uric acid (UA).

[0039] 3. Statistical methods

[0040] SPSS 20.0 software was used for statistical processing. Quantitative data were expressed as mean ± standard deviation (x±s). Normality and homogeneity of variance tests were performed on all data. For data that met the normality requirement, one-way ANOVA was used for multiple groups of quantitative data. A p-value < 0.05 was considered statistically significant.

[0041] III. Experimental Results

[0042] 1. Joint swelling

[0043] The results of joint swelling are shown in Table 1 below. The results show that the joint swelling rate in the model group was significantly higher than that in the normal control group, indicating successful model establishment. Compared with the model group, the joint swelling rates in the positive control group and the low / medium / high dose groups of sanguisorbin were significantly reduced, especially in the high dose group, whose effect was basically equivalent to that of the positive control drug colchicine. The results indicate that sanguisorbin can significantly reduce joint swelling in mice with acute gouty arthritis and alleviate tissue damage.

[0044] Table 1. Results of joint swelling in mice in each group ( n=10)

[0045]

[0046] Note: Compared with the normal control group, *P<0.01; compared with the model group, #P<0.01.

[0047] 2. Inflammatory factor levels

[0048] The levels of inflammatory factors are shown in Table 2 below. The results showed that, compared with the normal control group, the levels of inflammatory factors IL-1β and TNF-α in the model group were significantly increased. Compared with the model group, the levels of inflammatory factors IL-1β and TNF-α in the positive control group and the low / medium / high dose groups of sanguisorbin were significantly decreased, especially in the high dose group of sanguisorbin, whose effect was basically equivalent to that of the positive control drug colchicine. The results indicate that sanguisorbin can significantly reduce the levels of inflammatory factors IL-1β and TNF-α in mice with acute gouty arthritis, effectively alleviating inflammation.

[0049] Table 2 Results of inflammatory factor levels in mice of each group ( n=10)

[0050]

[0051] Note: Compared with the normal control group, *P<0.01; compared with the model group, #P<0.01.

[0052] 3. Blood uric acid

[0053] The serum uric acid results are shown in Table 3 below. The results indicate that serum uric acid levels in the model group were significantly higher than those in the normal control group. Compared to the model group, the serum uric acid level in the positive control group was only slightly lower, with no significant difference, which is consistent with the finding that colchicine has no uric acid-lowering effect. However, compared to the model group, serum uric acid levels in the low / medium / high dose groups of sanguisorbin were significantly lower, indicating that sanguisorbin has a certain uric acid-lowering effect. These results demonstrate that sanguisorbin can significantly reduce serum uric acid levels in mice with acute gouty arthritis and also has a certain therapeutic effect during the remission period of gout.

[0054] Table 3. Serum uric acid results in each group of mice ( n=10)

[0055]

[0056] Note: Compared with the normal control group, *P<0.01; compared with the model group, #P<0.01.

[0057] In summary, sanguisorbin can significantly alleviate joint swelling and tissue damage in acute gouty arthritis by inhibiting the release of inflammatory factors such as IL-1β and TNF-α, and can also reduce serum uric acid levels to a certain extent, thus possessing the potential to treat gout.

[0058] The embodiments described above are merely illustrative of several implementations of the present invention, and while the descriptions are relatively specific and detailed, they should not be construed as limiting the scope of the invention patent. It should be noted that those skilled in the art can make various modifications and improvements without departing from the concept of the present invention, and these all fall within the protection scope of the present invention. Therefore, the protection scope of this invention patent should be determined by the appended claims.

Claims

1. Application of sanguisorbin in the preparation of drugs for treating gout.

2. The application according to claim 1, characterized in that, The application of the saponin in the preparation of drugs for treating acute gouty arthritis.

3. The application according to claim 1, characterized in that, The application of sanguisorbin as the sole active ingredient in the preparation of drugs for treating gout.

4. The application according to claim 1, characterized in that, The medication mentioned for treating gout is an oral medication.

5. The application according to claim 4, characterized in that, The oral medication is in the form of tablets, capsules, powders, granules, or oral liquids.

6. The use of pharmaceutical compositions containing sanguisorbin in the preparation of drugs for treating gout.

7. The application according to claim 6, characterized in that, The use of the pharmaceutical composition containing sanguisorbin in the preparation of a medicament for treating acute gouty arthritis.

8. The application according to claim 6, characterized in that, In the pharmaceutical composition, sanguisorbin is the sole active ingredient.

9. The application according to claim 6, characterized in that, The pharmaceutical composition includes sanguisorbinogen and pharmaceutically acceptable excipients or carriers.

10. The application according to claim 6, characterized in that, The dosage form of the pharmaceutical composition is selected from tablets, capsules, powders, granules, or oral liquids.

Images